

10/568112

IAP5 Rec'd PCT/PTO 13 FEB 2006

Attorney Docket No. 1034123-000207

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Murray GOODMAN et al.

Group Art Unit: To Be Assigned

Application No.: To Be Assigned

Examiner: To Be Assigned

Filing Date: Herewith

Confirmation No.: To Be Assigned

Title: SOMATOSTATIN ANALOGS WITH INHIBITORY ACTIVITY TO GROWTH HORMONE RELEASE

FIRST  
INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed is a FIRST Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.


- No additional fee for submission of an IDS is required.
- The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- Charge \_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- A check in the amount of \_\_\_\_\_ is enclosed for the fee due.
- Charge \_\_\_\_\_ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL

By




Susan B. Fuller

Registration No. 51,979

Date: February 13, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

"Express Mail" Mailing Label No.: EV 793 689 261 US Date of Deposit: February 13, 2006



Kim A. Cabello

Typed Name:

**IAP5 Rec'd PCT/PTO 13 FEB 2006****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of  
Murray GOODMAN et al.

Application No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: Herewith

Examiner: To Be Assigned

For: SOMATOSTATIN ANALOGS WITH  
INHIBITORY ACTIVITY TO GROWTH  
HORMONE RELEASE

Confirmation No.: To Be Assigned

**FIRST INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. However, copies of the listed U.S. patents and U.S. patent application publications are not enclosed since it is no longer required according to the July 11, 2003 waiver of the requirement for copies of cited U.S. patents and U.S. patent application publications in national patent applications filed after June 30, 2003 and international applications entering the national stage under 35 U.S.C. § 371 after June 30, 2003.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

10/568112

FIRST Information Disclosure Statement

Application No. To Be Assigned

Attorney's Docket No. 1034123-000207

JAPS Rec'd PCT/PTO 13 FEB 2006

Page 2

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BUCHANAN INGERSOLL LLP

Date February 13, 2006

By: Susan B. Fuller  
Susan B. Fuller  
Registration No. 51,979

12230 El Camino Real  
Suite 300  
San Diego, CA 92130-2090  
(858) 509-7300

Complete if Known

FIRST <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>(use as many sheets as necessary)</small>		Application Number	Unassigned
		Filing Date	Herewith
		First Named Inventor	Murray Goodman et al.
		Examiner Name	
Sheet	1	of	1
		Attorney Docket Number	034123-207

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	3,842,067			
	3,862,925			
	3,904,594			
	3,972,859			
	4,816,438			
	5,436,155			
	5,620,675			
	5,668,006			
	5,716,596			
	5,929,209			
	6,001,801			
	6,602,849			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng Lang. Summary	Search Report	IPER	Cited in Spec	Abstract
	8927255.3		EP								
	WO 93/18797		WIPO								

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Bakker et al. (1991). <i>J. Nucl. Med.</i> , 32:1184-1189.
	Bussey, H. et al. (1995). <i>Proc. Natl. Acad. Sci.</i> , 92:3809-3813.
	Pradayrol, L. et al. (1980). <i>FEBS Letters</i> , 109:55-58.
	Raynor et al. (1993). <i>Mol Pharm</i> , 43:838-844.
	Smith-Jones et al. (1999). <i>Endocrinology</i> , 140:5136-5148.
	Woltering et al. (1994). <i>Surgery</i> , 116:1139-1147.

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.  
CA 100532.1